fda remove semaglutide from shortage list ban The FDA has removed semaglutide injection products (GLP-1) the U.S. judge upholds FDA's removal

Wear protective clothing and seek shade when outdoors

131 , e146353 (2021)

This offers several potential benefits: Avoids first-pass metabolism : Unlike swallowed medications that must pass through the liver, sublingual absorption delivers drugs directly to the bloodstream Bypasses stomach acid : GLP-1 peptides are degraded by digestive enzymes, so avoiding the stomach could improve stability Rich vascular network : The area under the tongue has extensive blood vessels that allow rapid absorption However, research on peptide delivery through oral mucosa reveals significant challenges: Peptides like semaglutide and tirzepatide have molecular weights around 4000 Da (compounds above 500 Da generally show poor permeability) Salivary and mucosal proteases degrade peptides before they can cross the epithelial barrier Continuous saliva production dilutes and washes away the medication Studies with insulin showed only 1-2% bioavailability via buccal/sublingual routes without absorption enhancers The key question: Do compounded ODT formulations overcome these barriers

Pharmacists When counselling patients who are starting a GLP-1 receptor agonist, inform them of the potential for delayed gastric emptying and the associated risk if they are to undergo any procedures or imaging that involves anesthesia (for which a fasting period or empty stomach is required)

Processed meats: Bacon, sausage, hot dogs

Ralentissement de la digestion : la vidange gastrique est plus lente, ce qui prolonge la sensation de ventre plein